A pilot study found that all patients with acute HCV who were treated with a direct-acting antiviral treatment over a short-duration of six weeks had undetectable HCV after a 12 week follow-up.
The investigator-initiated study has demonstrated that the combination of Sofosbuvir and Ledipasvir ( Harvoni ) for only six weeks is sufficient to treat patients with acute HCV.
Those infected with HCV usually develop acute hepatitis C, which spontaneously clears in 10 to 50% of infected persons. Early diagnosis of HCV infection is rare and the disease may go unnoticed until patients have already developed serious liver damage.
Sofosbuvir and Ledipasvir is one possible regimen for treatment of patients with chronic HCV.
Sustained virologic response ( SVR ) is greater than 95% with a 12-week course of this treatment.
The German pilot study, performed by the German HepNet Study-House, included 20 patients. Risk factors of HCV infection among the study members included; sexual transmission ( n=11 ), medical procedures/needle stick injury ( n=5 ), drug use ( n=1 ), and nail treatment complications ( n=1 ). The causes were unspecified for the remaining two patients.
All 20 patients completed six weeks of Sofosbuvir and Ledipasvir without Ribavirin. At the 12 week follow up, all 20 patients had undetectable HCV and achieved SVR ( 100% ).
Fatigue was the most frequent side effect reported by study members ( 30% ).
Source: The International Liver Congress, 2016